ENT Liu Knowledge Base Head & neck tumours · physician reviewed
Hypopharyngeal Cancer · Understanding the disease

Where in the world is hypopharyngeal cancer most common?

Reviewed: 8 November 2026 By: Xiangpeng Liu, MD Topic: Hypopharyngeal Cancer Answer length: short, citable
Quick answer

Hypopharyngeal Cancer is not evenly distributed: the highest-burden regions are Eastern Europe & the Baltic states, South-Central Asia / Bangladesh and India. In 2022 there were about 86,300 new hypopharyngeal cancer cases worldwide worldwide (male ASR 1.6 and female ASR 0.3 per 100,000; 11.4% of all lip/oral/pharyngeal cancers in 2022), with marked country-to-country variation driven by local exposures such as tobacco, areca nut, oncogenic viruses, ultraviolet radiation and occupational carcinogens.

In detail

The regional pattern matters clinically. A patient from Eastern Europe & the Baltic states may present with a different risk-factor profile and a different stage distribution than a patient from a low-incidence country, which changes both the differential diagnosis and the pretreatment work-up.

All incidence figures on this site are age-standardised rates or absolute case counts from GLOBOCAN 2022 and its subsite analyses. They describe populations, not individual risk.

  • Eastern Europe & the Baltic states: Hypopharyngeal cancer makes up 15.8% of the region’s lip/oral/pharyngeal burden — the highest regional share. Male ASRs above 5.0 are reported in Hungary, Slovakia, Belarus and Lithuania.
  • South-Central Asia / Bangladesh: 15.3% of the regional burden. Bangladesh has the highest ASR worldwide in both sexes (male 9.3, female 1.6); India’s ASIR is reported at 2.1 per 100,000.
  • India: High absolute burden from smoking, bidi use, chewing tobacco and alcohol, frequently with late-stage presentation and nutritional deficiency.
  • France & Western Europe: Historically elevated rates of hypopharyngeal and supraglottic cancer associated with combined tobacco and alcohol exposure.
  • North America & Australia: Rates are substantially lower and have generally declined with smoking cessation; the oropharynx (HPV-driven) is now the dominant pharyngeal subsite.

What this means in practice: this answer is part of the “Understanding the disease” section of the Hypopharyngeal Cancer topic. If you are comparing treatment options, also read how to compare a second opinion and which records to send.

Other common questions about hypopharyngeal cancer

See all 13 questions in this topic →

Sources for this answer

  1. Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 CA: A Cancer Journal for Clinicians · 2026 · Subsite-level estimates for 185 countries; the basis of the regional atlas on this site.
  2. Global Cancer Observatory (GLOBOCAN 2022) International Agency for Research on Cancer / WHO · 2022 · Source of worldwide and country-level incidence and mortality estimates.
  3. Global Cancer Facts & Figures, 5th Edition (GLOBOCAN 2022 tables) American Cancer Society · 2024
  4. Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 CA: A Cancer Journal for Clinicians · 2026 · Subsite-level estimates for 185 countries; the basis of the regional atlas on this site.
  5. Head and neck cancer: a comprehensive review of epidemiology, global burden and advances in radiotherapy PubMed Central / peer-reviewed review · 2026
  6. Global Cancer Observatory (GLOBOCAN 2022) International Agency for Research on Cancer / WHO · 2022 · Source of worldwide and country-level incidence and mortality estimates.
  7. Hypopharyngeal Cancer Treatment (PDQ, health professional version) US National Cancer Institute · 2025

Written and medically reviewed by Xiangpeng Liu, MD

Associate Chief Physician, ENT & Head/Neck Surgery · Chenzhou First People’s Hospital, Chenzhou, Hunan, China

Editorial policy & reviewer credentials · All sources

← Previous questionWhat is hypopharyngeal cancer? Next question →What are the risk factors for hypopharyngeal cancer?

Need an opinion on your own case?

International patients can request a preliminary review based on pathology and imaging before travelling to China.

How the pathway works Send an enquiry

Medical disclaimer: This knowledge base is general information for people researching head and neck tumours, not a diagnosis or treatment plan. It does not replace an examination by a qualified physician. Survival figures are population averages, not predictions for an individual. Treatment and cost estimates for China are illustrative only and must be confirmed in writing after your records have been reviewed. If you have a symptom lasting more than two to three weeks, see a doctor promptly.